Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Bergmann

Showing results (131-140 of 136) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 136 results.
Circulation|April 1, 1991
Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-lifeC J Weinheimer, H L James, N K Kalyan, et al.
Journal of the American College of Cardiology|September 1, 1992
Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolismR J Gropler, E M Geltman, K Sampathkumaran, et al.
Journal of the American College of Cardiology|November 15, 1993
Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomographyR J Gropler, E M Geltman, K Sampathkumaran, et al.
The New England Journal of Medicine|March 8, 1984
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarctionF Van de Werf, P A Ludbrook, S R Bergmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1990
Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusionM A Green, C J Mathias, M J Welch, et al.
Advances in Experimental Medicine and Biology|January 1, 1990
Biological properties of hybrid plasminogen activatorsP P Hung, J Wilhelm, N K Kalyan, et al.
Pageof 14

Showing results (131-140 of 136) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 136 results.
Circulation|April 1, 1991
Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-lifeC J Weinheimer, H L James, N K Kalyan, et al.
Journal of the American College of Cardiology|September 1, 1992
Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolismR J Gropler, E M Geltman, K Sampathkumaran, et al.
Journal of the American College of Cardiology|November 15, 1993
Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomographyR J Gropler, E M Geltman, K Sampathkumaran, et al.
The New England Journal of Medicine|March 8, 1984
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarctionF Van de Werf, P A Ludbrook, S R Bergmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1990
Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusionM A Green, C J Mathias, M J Welch, et al.
Advances in Experimental Medicine and Biology|January 1, 1990
Biological properties of hybrid plasminogen activatorsP P Hung, J Wilhelm, N K Kalyan, et al.
Pageof 14